Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluproxadine (18f)
- Development stage
- Unknown
- Lead developer
- University Hospital Würzburg
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
fluproxadine (18f) (formerly [18F]AF78) is a novel fluorine-18-labeled positron emission tomography (PET) radiotracer designed to target the norepinephrine transporter (NET). Developed by researchers at the University Hospital Würzburg, Okayama University, and collaborating institutions, it features a phenethylguanidine scaffold that provides high affinity for NET, comparable to that of endogenous norepinephrine. The tracer is designed for the non-invasive assessment of cardiac sympathetic nerve conditions (such as in congestive heart failure) and the delineation of neuroendocrine tumors (such as neuroblastoma and pheochromocytoma/paraganglioma). Its streamlined, one-step radiosynthesis using an unprotected guanidine precursor overcomes the complex, multi-step radiosynthetic challenges of legacy NET tracers, facilitating clinical translation.
- Other names
- [18F]-1-(3-fluoro-4-(3-fluoropropoxy)phenethyl)guanidine[18F]fluproxadinefluproxadinefluproxadine (18F)
02
Targets
NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on fluproxadine (18f).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluproxadine (18f).